Heart rate reduction and exercise performance in recent onset heart failure with reduced ejection fraction: arguments for beta-blocker hypo-response

References

• Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH.The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334:1349–55.
   Google Scholar
• The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353:9–13.
   Google Scholar
• Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001–7.
   Google Scholar
• Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P. Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651–8.
   Google Scholar
• McMurray JJ, Adamopoulos 5, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P. Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P. Knuuti J, Kolh P. McDonagh T, Moulin C, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker 5, Bonet LA, Avraamides P. Ben Lamin HA, Brignole M, Coca A, Cowburn P. Dargie H, Elliott P. Flachskampf FA, Guida GF, Hardman 5, lung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn 5, Parissis JT, Ponikowski P. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14:803–69.
   Google Scholar
• Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Drazner MH, Fonarow GC, Geraci SA, Norwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 128: e240–327.
   Google Scholar
• Barner HB, Jellinek M, Kaiser GC. Effects of isoproterenol infusion on myocardial structure and composition. Am Heart J 1970; 79: 237–43.
   Google Scholar
• Engelhardt 5, Hein L, Wiesmann F, Lohse MJ. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci US A 1999; 96: 7059–64.
   Google Scholar
• Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P. Ferguson D, Wolfel EE, Lindenfeld J, Tsvetkova T, Robertson AD, Quaife RA, Bristow MR. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 2002; 346: 1357–65.
   Google Scholar
• Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 2005; 111: 2837–49.
   Google Scholar
• Lechat P. Hulot JS, Escolano 5, Mallet A, Leizorovicz A, Werhlen-Grandjean M, Pochmalicki G, Dargie H. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001; 103: 1428–33.
   Google Scholar
• Pocock SJ, Wang D, Pfeffer MA, Yusuf 5, McMurray JJ, Swedberg KB, Ostergren J, Michelson EL, Pieper KS, Granger CB. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2006; 27:65–75.
   Google Scholar
• Bohm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised Placebo-controlled trial. Lancet 2010; 376:886–94.
   Google Scholar
• Swedberg K, Komajda M, Bohm M, Borer J, Robertson M, Tavazzi L, Ford I. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the l(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol 2012; 59: 1938–45.
   Google Scholar
• Volterrani M, Cice G, Caminiti G, Vitale C, D’Isa 5, Perrone Filardi P. Acquistapace F, Marazzi G, Fini M, Rosano GM. Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial). IntiCardiol 2011; 151:218–24.
   Google Scholar
• Castro P. Vukasovic JL, Chiong M, Diaz-Araya G, Alcaino H, Copaja M, Valenzuela R, Greig D, Perez O, Corbalan R, Lavandero S. Effects of carvedilol on oxidative stress and chronotropic response to exercise in patients with chronic heart failure. Eur J Heart Fail 2005; 7: 1033–9.
   Google Scholar
• Jorde UP, Vittorio TJ, Kasper ME, Arezzi E, Colombo PC, Goldsmith RL, Ahuja K, Tseng CH, Haas F, Hirsh DS. Chronotropic incompetence, beta-blockers, and functional capacity in advanced congestive heart failure: time to pace? Eur J Heart Fail 2008; 10: 96–101.
   Google Scholar
• Magri D, Palermo P. Cauti FM, Contini M, Farina 5, Cattadori G, Apostolo A, Salvioni E, Magini A, Vignati C, Alimento M, Sciomer 5, Bussotti M, Agostoni P. Chronotropic incompentence and functional capacity in chronic heart failure: no role of beta-blockers and beta-blocker dose. Cardiovasc Ther 2012; 30: 100–8.
   Google Scholar
• Duchenne J, Verbrugge FH, Dupont M, Vercammen J, Jacobs L, Grieten L, Vandervoort P. Mullens W. Implementation of transmural disease management in patients admitted with advanced heart failure. Acta Cardiol 2014; 69: 145–54.
   Google Scholar
• Flannery G, Gehrig-Mills R, Billah B, Krum H. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 2008; 101:865–9.
   Google Scholar
• McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009; 150: 784–94.
   Google Scholar
• Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376:875–85.
   Google Scholar
• den Hoed Metal. Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders. Nat Genet 2013; 45: 621–31.
   Google Scholar
• Maack C, Cremers B, Flesch M, Hoper A, Sudkamp M, Bohm M. Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium. Br J Pharmacol 2000; 130: 1131–9.
   Google Scholar
• Maack C, Elter T, Nickenig G, LaRosee K, Crivaro M, Stablein A, Wuttke H, Bohm M. Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure. J Am Coll Cardiol 2001; 38: 939–46.
   Google Scholar